Panacea Pharmaceuticals, Inc. to Present at BIO CEO & Investor Conference

Webcast will be Available Wednesday, February 21, 2001

ROCKVILLE, Md.--(BW HealthWire)--February 16, 2001--Panacea Pharmaceuticals, Inc. announced today that it will present at the BIO CEO & Investor Conference at the Waldorf Astoria Hotel in New York City on Tuesday, February 20, 2001.

Hossein A. Ghanbari, Ph.D., President and CEO of Panacea, will give the presentation.

Internet users can link to the webcast from the home page of Panacea Pharmaceuticals' web site at www.panaceapharma.com or at www.informedinvestors.com. The presentation will also be available on a replay basis on the Panacea web site for approximately three months following the webcast.

The webcast is being provided by InformedInvestors.com, the leading producer of online and off line industry-specific investment conferences for individual investors.

InformedInvestors.com is among the largest investor-communications firms in the world, offering a growing stable of resources for in-depth sector-analysis while serving 4,000 companies and reaching millions of investors, including 1.4 million registered users.

The BIO CEO & Investor Conference is a neutral forum where CEOs from small, medium, and large cap companies, as well as private companies planning to go public, can interact with investors and other members of the financial community and the healthcare industry.

The conference provides an opportunity to promote the entire biotechnology industry and is supported by the leading investment banks, pharmaceutical companies, and healthcare organizations, as well as key industry advisors and observers. More information is available at www.investinbio.org.

About Panacea Pharmaceuticals

Panacea Pharmaceuticals, Inc. focuses on developing and utilizing protein-based technologies to detect and identify changes associated with and involved in diseases of the central nervous system and cancer such as Alzheimer's disease, brain tumors, transmissible spongiform encephalopathies, and Lewy body diseases such as Parkinson's disease.

Changes in disease-relevant proteins by altered expression, post-translational modification, and functional variation are utilized to develop diagnostic tests and therapeutic agents.